Nuformix
Nuformix is a UK-listed virtual pharmaceutical development company using solid-form science and drug repurposing to advance three preclinical/late-discovery assets — NXP001, NXP002, and NXP004 — for fibrosis and oncology, monetising them through out-licensing to pharmaceutical partners.
- Company typePublic
- Founded2017
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Nuformix does
Nuformix plc is a UK-domiciled, London Stock Exchange-listed (ticker NFX) pharmaceutical development company that applies solid-form science and drug-repurposing expertise to create differentiated formulations of marketed compounds for fibrosis and oncology indications. Founded in 2008 (rebranded from Levrett PLC in September 2017), the company operates a virtual R&D model: three Directors plus a scientific consultant oversee development outsourced to a contracted network, with no in-house laboratory infrastructure.
Its pipeline comprises three assets. NXP002 is an inhaled formulation of tranilast for idiopathic pulmonary fibrosis (IPF), which reported positive preclinical results in March 2023 and received FDA Orphan Drug Status in March 2026, conferring US tax credits, fee waivers, and seven years of market exclusivity. NXP001 is a proprietary new form of aprepitant for oncology supportive care, exclusively licensed to Oxilio Ltd in September 2021 in a deal yielding upfront, development milestones, and royalties on net sales capped at £2 million per annum. NXP004 consists of novel co-crystal forms of olaparib (an oncology drug with annual sales exceeding £1 billion); two patent applications filed in September 2020 and November 2021 could extend exclusivity to 2040/2041 if granted.
The business model is asset-centric licensing rather than product sales. Nuformix takes each asset to a value inflection point — typically preclinical proof-of-concept or regulatory designation — before seeking global out-licensing deals with pharmaceutical partners. Capital comes from periodic equity placings (March 2021, October 2024, May 2025, October 2025) supplemented by non-dilutive grant funding. No commercial product revenue is generated; near-term cash inflows depend on licensing milestones and royalties under the Oxilio agreement.
Nuformix firmographics
Firmographics- Name
- Nuformix
- Legal name
- Nuformix plc
- Website
- https://nuformix.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nuformix is a UK-listed virtual pharmaceutical development company using solid-form science and drug repurposing to advance three preclinical/late-discovery assets — NXP001, NXP002, and NXP004 — for fibrosis and oncology, monetising them through out-licensing to pharmaceutical partners.
- Ownership category
- akta.pro rank
Where Nuformix is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Nuformix business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Licensing Revenue: The company generates revenue through licensing its proprietary drug candidates to pharmaceutical partners. This includes upfront payments, development milestone payments, and royalties on net sales. For NXP001 licensing with Oxilio, Nuformix receives an undisclosed upfront payment, development milestone payments, and a royalty on net sales capped at £2 million per annum.
- Non-dilutive Grant Funding: The company seeks ongoing non-dilutive grant funding for early-stage assets that, if successful, will enable further investment in the pipeline to accelerate development and potential licensing opportunities.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
Nuformix product offering
Product offeringCore offering
Nuformix is a pharmaceutical development company that uses proprietary solid form science and cocrystal technology to discover, develop and patent novel drug forms of marketed compounds, repurposing them into differentiated therapeutic candidates for fibrosis and oncology. The company operates a virtual development model, advancing assets to key value inflection points before licensing them to pharmaceutical partners for upfront fees, development milestones, and royalties.
Product overview
Nuformix is a pharmaceutical development company with an early-stage pipeline of three preclinical and Phase 1-ready assets targeting fibrosis and oncology through drug repurposing. The company's core products include NXP002 (inhaled tranilast for idiopathic pulmonary fibrosis), NXP001 (novel form of aprepitant for oncology, licensed to Oxilio), and NXP004 (novel form of olaparib for oncology). Nuformix uses expertise in solid form science to discover, develop, and patent novel drug forms with improved physical properties to create differentiated products in new indications.
Differentiator
Problem solved
Functional benefit
Products and services
- NXP002 (inhaled tranilast) Lead asset and potential novel inhaled treatment for idiopathic pulmonary fibrosis (IPF). An inhaled formulation of tranilast delivered directly to the lungs by inhalation, targeting TGFβ/SMAD2-mediated extra-cellular matrix protein production. Preclinical data demonstrated efficient lung delivery with significant drug levels and limited systemic exposure compared to oral dosing, and dose-dependent regulation of fibrosis-relevant mediators.
- NXP001 (proprietary new form of aprepitant) Proprietary new form of aprepitant for oncology supportive care and oncology indications, demonstrating bioavailability similar to the marketed product without requiring complex formulation. Out-licensed exclusively to Oxilio Ltd on 10 September 2021 for global research, development and commercialisation in oncology indications in exchange for undisclosed upfront, development milestones, and royalties on net sales capped at £2 million per annum.
- NXP004 (novel co-crystal forms of olaparib)
Quantifiable outcome
- Shares increased 12.5% following FDA Orphan Drug Status grant for NXP002
- +2 more outcomes
Companies that use Nuformix
Customer profileSegments2 records
Ideal customer profiles1 record
Nuformix technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Nuformix partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Oxilio LtdcoreExclusive global licensing agreement signed on September 10, 2021 with Oxilio Ltd, a privately held pharmaceutical development company, for NXP001 (proprietary new form of aprepitant) for oncology indications. Oxilio obtained an exclusive licence to research, develop and commercialise NXP001 globally for oncology indications. Nuformix is eligible to receive an undisclosed upfront payment, development milestone payments, and a royalty on net sales capped at £2 million per annum.
Scale indicators3 records
Recent moves7 records
Expansion highlights4 records
Nuformix competitors and assessment
Company assessmentBroad incumbents
- PureTech Health: Clinical-stage biotech that develops and de-risks therapeutic candidates before partnering or spinning out — comparable platform-company model to Nuformix's licensing approach.
- FibroGen: Develops pamrevlumab for IPF and other fibrosis indications — incumbent competitor shaping the IPF market dynamics that NXP002 would enter.
- Roivant Sciences: Operates a 'Vant' structure of focused subsidiaries developing and licensing differentiated drug candidates — the gold-standard virtual pharma licensing model that Nuformix aspires to emulate.
Direct peers
- e-Therapeutics: UK-listed small-cap pharma using computational and network biology approaches to discover and repurpose existing drugs — directly comparable to Nuformix's repurposing and licensing strategy.
- Verona Pharma: UK-listed respiratory-focused biotech developing novel inhaled therapies — directly comparable inhaled-delivery approach in respiratory disease.
- Cyclacel Pharmaceuticals: Early-stage oncology-focused small-cap biotech with multiple clinical assets — comparable as a small publicly-listed pharma developer reliant on licensing/out-licensing outcomes.
- Redhill Biopharma: Specialty pharma focused on late-stage clinical assets and out-licensing/partnering of differentiated formulations — closely aligned with Nuformix's licensing-driven model.
- Tiziana Life Sciences: UK-listed small-cap biotech with a lean virtual operating model and licensing focus — directly comparable structure and scale to Nuformix.
Emerging players
- Silence Therapeutics: UK-based clinical-stage biotech with a focused pipeline and partnering-led commercial strategy — similar small-cap UK public-company profile and asset-partnering trajectory.
- Pliant Therapeutics: Clinical-stage biotech focused on fibrosis therapeutics, including IPF — directly relevant as a competitor and comparable developer in Nuformix's lead indication.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Nuformix social profiles
Digital presenceNuformix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nuformix leadership team
Management profileNumber of profiles
Profiles4 records
Nuformix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nuformix M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nuformix
What does Nuformix do?
Nuformix is a pharmaceutical development company that uses proprietary solid form science and cocrystal technology to discover, develop and patent novel drug forms of marketed compounds, repurposing them into differentiated therapeutic candidates for fibrosis and oncology. The company operates a virtual development model, advancing assets to key value inflection points before licensing them to pharmaceutical partners for upfront fees, development milestones, and royalties.
Is Nuformix a public or private company?
Nuformix is a public company. It is classified as public and is currently operating.
When was Nuformix founded?
Nuformix was founded in 2017. It employs 1 to 10 people.
Where is Nuformix based?
Nuformix is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Nuformix make money?
Two revenue lines are on record. Licensing Revenue is the primary driver. The others are non-dilutive Grant Funding.
Who are Nuformix's main competitors?
Broad incumbents on record are PureTech Health, FibroGen and Roivant Sciences. Direct peers are e-Therapeutics, Verona Pharma, Cyclacel Pharmaceuticals, Redhill Biopharma and Tiziana Life Sciences. Emerging players are Silence Therapeutics and Pliant Therapeutics.
Does Nuformix have an API?
No public API is recorded for Nuformix.